Drug intelligence / Profile preview

SRD-006

Development stage: Preclinical
Lead developer: Sardocor
Modality: Gene Therapies

Overview

SRD-006 is a gene therapy under development by Sardocor Corp. for the treatment of arteriovenous fistula failure, primarily targeting cardiovascular diseases and congenital disorders. The drug is currently in preclinical development and is designed to address complications associated with arteriovenous fistulas, which are commonly used in hemodialysis patients. Specific details regarding its mechanism of action or molecular target have not been disclosed[1].

Other names: AV Fistula Failure gene therapy Sardocorarteriovenous Fistula Failure Sardocor

Beyond the preview

Go deeper on SRD-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRD-006.

Explore the full profile